BillionToOne, Inc. (NASDAQ:BLLN) shares fell 28.12% in Wednesday’s after-hours session after the company reported its second-quarter financial results.

The stock closed Wednesday’s regular session up 5.43% at $149.97 before falling 28.12% to $107.80 in after-hours trading.

BillionToOne is a molecular diagnostics company that develops genetic testing products for prenatal and oncology applications using its proprietary DNA counting technology.

Quarter Results

For the quarter ended June 30, 2026, BillionToOne reported revenue of $109.4 million, up from $66.6 million in the prior-year period. Net income was $8.1 million, or $0.15 per diluted share, compared with a net loss of $0.2 million, or $(0.02) per diluted share, a year earlier.

The company delivered 196,000 tests during the quarter, a 35% increase from a year ago, while gross profit margin improved to 70% from 65%. Income from operations was $5.5 million, compared with an operating loss of $1.6 million in the prior-year period.

BillionToOne maintained its full-year 2026 revenue guidance of $450 million to $465 million and said it expects to continue generating profitability while investing in the business. The company also announced the upcoming commercial launches of its expanded Unity Fetal Risk Screen on Aug. 17 and Northstar Origin on Sept. 1.

Trading Metrics

BillionToOne has a market capitalization of approximately $6.90 billion, with a 52-week high of $150.44 and a 52-week low of $61.96.

Over the past 12 months, BLLN shares have gained approximately 37.66%.

Benzinga Edge Stock Rankings show positive price trends across the short-, medium- and long-term time frames.

Disclaimer: This content was produced with the help of AI tools and was reviewed and published by Benzinga editors.

Photo: Who is Danny/Shutterstock